Clinical trials: sponsored by The Methodist Hospital Research Institute
Ureteral Stent-Related Symptom
Dexamethasone for Ureteral STent Symptoms (DUSTS)
The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones.
- Trial name
- DUSTS (NCT06930690)
- Testing
- Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Methodist Hospital Research Institute
ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Spinal Cord Injuries, Cervical Spinal Cord Injury
Augmenting Upper Limb Function and Functional Neuroplasticity Using Epidural Stimulation of the Cervical Spinal Cord
This study will test whether spinal stimulation combined with rehabilitation can improve arm and hand function in people with tetraplegia after spinal cord injury. Tetraplegia causes weakness or paralysis in the arms and legs.
- Conditions
- Spinal Cord Injuries, Cervical Spinal Cord Injury, Spinal Cord Injury
- Trial name
- NCT06225245
- Testing
- Epidural Spinal Stimulation (ESS), Upper extremity rehabilitation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus…
- Trial name
- NCT05185505
- Testing
- Atezolizumab, Bevacizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease…
- Trial name
- NCT07060001
- Testing
- 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Non-Small-Cell Lung
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative…
- Trial name
- NCT06566443
- Testing
- Honokiol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Methodist Hospital Research Institute
Hepatocellular Carcinoma
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma…
- Trial name
- NCT05171335
- Testing
- Lenvatinib, Transcatheter Arterial Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced or Metastatic CRC
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
This is a phase I study investigating the safety and antitumor activity of 5FU-based therapy (FOLFIRI/FOLFOX + Biologics) in combination with Hydroxytyrosol (HT) as a treatment for patients with advanced or metastatic colorectal…
- Trial name
- NCT06833866
- Testing
- Hydroxytyrosol
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Colorectal Cancer (CRC)
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.
- Trial name
- NCT06887218
- Testing
- Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced Small Intestine Cancer, Appendiceal Cancers
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
This study will evaluate the safety and efficacy of NALIRIFOX per NAPOLI-3 regimen as first-line chemotherapy for patients with advanced small intestine and appendiceal cancers.
- Trial name
- NCT07060014
- Testing
- Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- The Methodist Hospital Research Institute
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Stroke, Chronic Stroke
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement…
- Conditions
- Stroke, Chronic Stroke, Hemorrhage Brain, Ischemic Stroke
- Trial name
- NCT06286800
- Testing
- Transcranial direct current stimulation (tDCS) with OT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Bunion
LSTR in Chevron Osteotomy
The goal of this clinical trial is to determine if performing a lateral soft tissue release during a Chevron osteotomy (or Akin osteotomy when appropriate) for bunions leads to better correction without added complications in 200…
- Trial name
- NCT06486753
- Testing
- Chevron osteotomy bunion surgery with lateral soft tissue release
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Methodist Hospital Research Institute
Achilles Tendon Rupture
Effect of BFR Rehab After Achilles Tendon Rupture
The purpose of this study is to determine if blood flow restriction therapy after Achilles tendon rupture reconstruction decreases post-operative calf atrophy, improves reported outcomes, and ultimately decreases return to play…
- Trial name
- NCT06254794
- Testing
- Blood flow restriction with Delfi Personalized Tourniquet System (PTS), Physical therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic onabotulinumtoxinA (BOTOX®) administered before radical…
- Trial name
- NCT07796490
- Testing
- OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Device Convenience, Device Performance
Use of Apple Vision Pro as Virtual Monitor for Diagnostic and Therapeutic Procedures
This study evaluates whether the Apple Vision Pro (AVP), a head-mounted display device, can be used as a virtual monitor for performing diagnostic and therapeutic procedures.
- Conditions
- Device Convenience, Device Performance, Surgeons' Rating, Ergonomics
- Trial name
- NCT07797556
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplant, Kidney Donor
Transforming Curiosity Into Donation
This is a multi-step study that will first create a preliminary living donor drop-out risk index (LD-DROP) by retrospectively identifying factors that contribute to the discontinuation of living donor evaluation.
- Conditions
- Kidney Transplant, Kidney Donor, Drop Out, High Risk
- Trial name
- NCT07793890
- Testing
- Living Kidney Donor Support
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Kidney Disease, Kidney Transplant
Strategies to Transform Kidney Care and Improve Pursuit of Transplant
Approximately 15% of the U.S. population has chronic kidney disease, and ~700,000 patients are in full kidney failure also called end-stage kidney disease (ESKD).
- Conditions
- Kidney Disease, Kidney Transplant, Deceased Donor Kidney Transplant, Living Donor Kidney Transplantation
- Trial name
- NCT07794631
- Testing
- Digital Health Integration, Training for Early Transplant Access and Support, Kidney Health Mobile Health (mHealth) Application
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplant Donor
Modifiable Factors Affecting Racial Disparities in Kidney Donation
While many people offer to be evaluated at transplant centers as potential living donors to donate one kidney to someone they know, few ultimately donate. Racial/ethnic minorities are less likely to become living donors.
- Trial name
- NCT07793877
- Testing
- Not applicable- observational study
- Volunteers
- 2,332 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute